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SUMMARY
An increasing number of therapeutic antibodies targeting tumors that express the epidermal growth factor
receptor (EGFR) are in clinical use or late stages of clinical development. Here we investigate the molecular
basis for inhibition of EGFR activation by the therapeutic antibody matuzumab (EMD72000). We describe the
X-ray crystal structure of the Fab fragment of matuzumab (Fab72000) in complex with isolated domain III from
the extracellular region of EGFR. Fab72000 interacts with an epitope on EGFR that is distinct from the ligand-
binding region on domain III and from the cetuximab/Erbitux epitope. Matuzumab blocks ligand-induced
receptor activation indirectly by sterically preventing the domain rearrangement and local conformational
changes that must occur for high-affinity ligand binding and receptor dimerization.INTRODUCTION
The epidermal growth factor receptor (EGFR) is aberrantly
activated in a variety of epithelial tumors and has been the focus
of much interest as a target in anticancer therapy. EGFR is one of
a family of four receptor tyrosine kinases (collectively known as
the ErbB or HER receptors) that are involved in critical cellular
processes such as proliferation, differentiation, and apoptosis
(Hubbard and Miller, 2007; Schlessinger, 2000). Misregulation
of EGFR, through overexpression or mutation, leads to constitu-
tive activity or impaired receptor downregulation and can cause
malignant transformation of the cell (Mendelsohn and Baselga,
2006).
Based on structural studies over the past 5 years of the ErbB
receptors, a model has been proposed for ligand-dependent
dimerization and activation of EGFR (Figure 1) (Burgess et al.,
2003; Ferguson et al., 2003; Zhang et al., 2006). Dimerization of
the EGFR extracellular region is entirely receptor mediated,with the majority of interactions contributed by domain II of
EGFR (Garrett et al., 2002; Ogiso et al., 2002). In the unliganded
state, the receptor adopts a very different conformation that
occludes much of the domain II dimerization interface in an intra-
molecular interaction or tether with domain IV (Bouyain et al.,
2005; Cho and Leahy, 2002; Ferguson et al., 2003). Upon ligand
binding, theextracellular regionofEGFRmustundergoadramatic
domain rearrangement, which exposes the domain II dimerization
interface. Additional localized ligand-induced changes stabilize
the precise conformation of domain II that is required for dimer-
ization (Dawson et al., 2005). Receptor dimerization brings the in-
tracellular regions into close proximity, promoting the allosteric
activation of the kinase domains (Zhang et al., 2006).
This mechanism suggests a number of ways to inhibit EGFR
activation through interaction with the extracellular region of
the receptor (Ferguson, 2004). X-ray crystallographic and
biochemical analysis of receptor-antibody complexes have indi-
cated several modes of binding that lead to effective inhibition ofSIGNIFICANCE
Antibodies targeting the EGF receptor family are proven anticancer drugs. The anti-ErbB2 antibody trastuzumab/Herceptin
is established as a treatment of ErbB2-positive breast cancer, and therapeutic protocols are in clinical use for two EGFR-
targeting antibodies, cetuximab/Erbitux and panitumumab/Vectibix. Matuzumab, a humanized form of the mouse anti-
EGFR mAb425, is in phase II clinical trials. Our studies show that both the epitope for and the mechanism of inhibition by
matuzumab are distinct from those for cetuximab. We show that matuzumab and cetuximab can both simultaneously
bind to EGFR, implying that combination therapy with both antibodies could be advantageous. This has important implica-
tions for the clinical use of matuzumab and in moving forward with the development of therapeutic approaches targeting the
EGF receptor.Cancer Cell 13, 365–373, April 2008 ª2008 Elsevier Inc. 365
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Inhibition of EGFR by MatuzumabErbB receptor signaling. The chimeric antibody cetuximab/Erbi-
tux (Imclone/BMS and Merck KGaA) binds to domain III of EGFR,
directly blocking ligand binding (Li et al., 2005). Another anti-
EGFR antibody, mAb806, binds to domain II close to the recep-
tor dimerization site (Johns et al., 2004). The anti-ErbB2 antibody
pertuzumab/Omnitarg (Genentech) binds to the domain II dimer-
ization arm and prevents ligand-induced ErbB2 heterodimeriza-
tion (Franklin et al., 2004), while trastuzumab/Herceptin (Genen-
tech) binds to the membrane-proximal domain IV of ErbB2 (Cho
et al., 2003) and likely modulates a cleavage event that leads to
ectodomain shedding and kinase activation (Molina et al., 2001).
We were interested to establish the mode of inhibition of EGFR
by another therapeutic antibody, matuzumab (EMD72000),
which targets EGFR-expressing tumors. Matuzumab is the
humanized form of the murine mAb 425 (EMD55900) that was
produced by immunization of BALB/c mice with human A431
epidermoid carcinoma cells (Kettleborough et al., 1991; Murthy
et al., 1987). Monoclonal antibody 425 (EMD55900) blocks
ligand-dependent activation of EGFR in tumor cell lines (Rodeck
et al., 1990) and has been demonstrated to inhibit growth of
EGFR-dependent tumors in preclinical studies (Rodeck et al.,
1987). Matuzumab has performed well in phase I clinical trials
against a number of cancers, both alone and in combination
with chemotherapy (Bier et al., 2001; Graeven et al., 2006;
Kollmannsberger et al., 2006; Vanhoefer et al., 2004), and is
being actively pursued in multiple ongoing phase II trials (Seiden
et al., 2007; Socinski, 2007).
Here we describe the crystal structure of the Fab fragment of
matuzumab (Fab72000) bound to a truncated form of the extra-
cellular region of EGFR that comprises all of domain III plus the
first 24 amino acids from domain IV. Matuzumab binds to an
epitope on domain III of EGFR that is distinct from both the
Figure 1. Ligand-Induced EGF Receptor Dimerization
The extracellular region of the EGF receptor (sEGFR) is shown in cartoon
representation with domain I in red, domain II in green, and domains III and
IV in gray, with the secondary structure elements highlighted in red and green,
respectively. The inactive receptor (left-hand view) exists in a tethered, autoin-
hibited conformation with an intramolecular interaction between domains II
and IV. Upon ligand binding, the receptor adopts a very different domain
arrangement (right-hand view). Ligand (here EGF, shown in purple cartoon)
binds between domains I and III of a single EGFR molecule, stabilizing the pre-
cise, extended configuration of EGFR that can dimerize. All contacts between
the two molecules in the dimer are receptor mediated, with domain II providing
the primary dimerization contacts. EGF receptor dimerization is ligand
induced, but entirely receptor mediated. The colors on the right-hand molecule
in the sEGFR dimer have been muted for contrast. Coordinates from PDB IDs
1IVO and 1NQL were used to generate this figure. Domain IV in the sEGFR
dimer was modeled as previously described (Ferguson et al., 2003).366 Cancer Cell 13, 365–373, April 2008 ª2008 Elsevier Inc.ligand-binding site and the cetuximab epitope on that domain.
Matuzumab does not directly block the access of ligand to the
domain III-binding site, and thus does not share the primary
mechanism for inhibition of ligand-induced EGFR activation
employed by cetuximab. Rather, the binding of matuzumab to
domain III sterically blocks the domain rearrangement that is
required for high-affinity ligand binding and receptor dimeriza-
tion. Further, binding to this epitope places the antigen-binding
domains of matuzumab such as to impede the formation of the
critical contacts between domains II and III that are required to
stabilize the dimerization competent conformation of domain II.
This noncompetitive mechanism of inhibition of EGFR activation
has implications for both the application of current drugs and the
development of anti-EGFR therapeutics.
RESULTS AND DISCUSSION
Binding Characteristics of Matuzumab to Cell Surface
and Soluble EGFR
To determine the mode of binding of matuzumab to EGFR, and
to elucidate the mechanism of inhibition of EGFR by this thera-
peutic antibody, we sought to determine the X-ray crystal struc-
ture of the complex between the Fab fragment of the antibody
and the extracellular region of EGFR. We first characterized the
binding of matuzumab to the soluble extracellular domain of
EGFR (sEGFR) and compared the results to the behavior of
this antibody in cell surface binding assays.
Soluble EGFR was produced by secretion from baculovirus-
infected Sf9 cells and purified exactly as described (Ferguson
et al., 2000). The Fab fragment of matuzumab (Fab72000),
produced by papain cleavage of the antibody, was immobilized
on a CM5 biosensor chip (see Experimental Procedures). Using
surface plasmon resonance (SPR/Biacore), we established that
sEGFR binds to this immobilized Fab72000 with a KD value of
113 ± 25 nM (Figure 2A). This value is weaker than that observed
for the binding of 125I-labeled intact matuzumab to cell surface
EGFR (about 1–10 nM, depending on the cell line employed;
data not shown), although these binding assays are not directly
comparable. It has previously been shown that the epitope for
cetuximab lies exclusively on domain III of sEGFR (Li et al.,
2005). To address whether this is also true for matuzumab, we
produced and purified isolated domain III of sEGFR (sEGFRd3;
amino acids 311–514 of mature EGFR) exactly as described
(Li et al., 2005). As shown in Figure 2A, sEGFRd3 binds to immo-
bilized Fab72000 with a KD value of 43.0 ± 12.9 nM. The antigen-
binding domain of matuzumab, like that of cetuximab, binds
more tightly to sEGFRd3, possibly due to the absence of steric
hindrance from the other domains of sEGFR.
We next used both SPR and cell surface binding analysis to
investigate the ability of matuzumab to compete with ligand
binding to EGFR. As shown in Figure 2B, matuzumab, like cetux-
imab, competes efficiently for the binding of 3 nM 125I-labeled
EGF to the surface of A431 epidermoid carcinoma cells. It has
previously been shown that, in the context of an SPR/Biacore
assay, the Fab fragment of cetuximab (FabC225) is able to block
all binding of soluble sEGFR to immobilize EGF (Li et al., 2005).
We asked if this is also true for the Fab fragment of matuzumab.
Samples of 600 nM sEGFR containing increasing excesses of
Fab72000 were passed over a biosensor surface to which EGF
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Inhibition of EGFR by Matuzumabhad been immobilized. As shown in Figure 2C, there is an initial
decrease in the equilibrium SPR response as increasing
Fab72000 is added. At a 1:1 molar ratio of Fab72000:sEGFR,
the SPR response is about 45% of that obtained with no added
Fab. Addition of increasing excesses of Fab72000 does not fur-
ther reduce this binding level. Even at a higher concentration of
sEGFR and with up to a 50-fold excess of Fab72000 (data not
shown), the equilibrium SPR response does not fall below 40%
of the value in the absence of added Fab. One possible explana-
Figure 2. Characterization of the EGFR-Binding and Ligand
Competition Properties of Matuzumab
(A) Surface Plasmon Resonance (SPR) analysis of the binding of sEGFR and
sEGFRd3 to immobilized Fab72000 (the antigen-binding domain of matuzu-
mab). A series of samples of sEGFR or sEGFRd3, at the indicated concentra-
tions, was passed over a biosensor surface to which Fab72000 had been
amine coupled. Data points show the equilibrium SPR response value for a
representative set of samples of sEGFR (black squares) and of sEGFRd3
(open triangles), expressed as a percentage of the maximal SPR-binding
response. The curves represent the fit of these data to a simple one-site Lang-
muir binding equation. KD values, based on at least three independent binding
experiments, are 113 ± 25 nM for sEGFR and 43 ± 13 nM for sEGFRd3.
(B) Competition of EGF (green diamonds), matuzumab (red triangles), or cetux-
imab (black triangles) for the binding of 125I-labeled EGF to A431 cells. Cells
were incubated with media containing 3 nM 125I-labeled EGF plus the indi-
cated concentration of cold matuzumab, cetuximab, or EGF for 6 hr at 4C.
Following washing to remove unbound material, cells were lysed and liquid
scintillation counting was used to determine the amount of bound 125I-labeled
EGF. The counts per minute (CPM) for each sample are shown, expressed as
a percentage of the CPM value obtained for no added competitor. Error bars
indicate the standard deviation on three independent experiments. The line
indicates the fit to a sigmoidal dose-response model. IC50 values from this
analysis are 2.0 nM for matuzumab and cetuximab and 7.3 nM for EGF.
(C) A competition experiment showing the effect of addition of Fab72000 upon
the binding of 600 nM sEGFR to immobilized EGF. Mixtures of 600 nM sEGFR
plus the indicated concentrations of Fab72000 were passed over a biosensor
surface to which EGF had been amine coupled. The equilibrium SPR
responses for each mixture is shown, normalized to the response obtained
with no added Fab. Error bars indicate the standard deviation on at least three
independent measurements. The line simply connects the data points.
(D) The ability of FabC225 (the antigen-binding domain of cetuximab; gray
shades) and Fab72000 (red shades) to compete for the binding of 600 nM
sEGFR to immobilized EGF, determined exactly as described in (C). Samples
of each Fab alone show no binding to the immobilized EGF (data not shown).
Data for FabC225 taken from Li et al. (2005). Error bars indicate the standard
deviation on at least three independent measurements.tion for the observed SPR responses in Figure 2C is that both
unbound sEGFR and the Fab72000/sEGFR complex can interact
with the immobilized EGF, but that the complex binds with
substantially weaker affinity. Equilibrium binding analysis to
immobilized EGF for samples of sEGFR containing a 10-fold
molar excess of Fab72000 indicates an apparent KD value that
is approximately 5-fold weaker than that for sEGFR alone (data
not shown). Certainly these data suggest that there must be
something quite different about the mode of binding to sEGFR
of the Fab fragment of matuzumab compared to that of cetuxi-
mab. Both antibodies are able to compete for binding of low
concentrations of EGF to cell surface EGFR, yet the Fab frag-
ments from the two antibodies have very different effects on
the ability of soluble EGFR to bind to immobilized EGF in the
Biacore assay (Figure 2D and Li et al., 2005).
To gain further insight into the precise mode of binding of
matuzumab to EGFR, and to understand how this leads to inhi-
bition of cell surface ligand binding and of ligand-stimulated
EGFR activation, we crystallized and solved the structures of
Fab72000 alone and in complex with the sEGFRd3 (see Experi-
mental Procedures and Table 1).
The Structure of the Fab72000/sEGFRd3 Complex
Crystals of the isolated Fab72000 that diffract to 2.15 A˚ resolu-
tion were obtained, and the structure was solved by molecular
replacement (MR) methods using as search model the coordi-
nates of an Fab fragment selected by degree of sequence
similarity (Protein Data Bank [PDB] ID 1L7I). A complex of
sEGFRd3 and Fab72000 was purified by size exclusion chroma-
tography (SEC), and crystals that diffract to 3.2 A˚ resolution were
obtained using streak seeding techniques. To solve this struc-
ture, MR search models based on the coordinates for domain
III of sEGFR (PDB ID 1YY9) and the coordinates of the refined
Fab72000 were used to locate the two Fab72000/sEGFRd3
complexes in the asymmetric unit. Data collection and refine-
ment statistics are given in Table 1.
Fab72000 binds primarily to the loop that precedes the most
C-terminal strand of the domain III b-helix (amino acids
454–464; highlighted in red in Figure 3A). This loop penetrates
into a cleft between the VL and VH domains of the Fab. The tip
of this loop forms a type I beta turn, with T459 and S460 in this
turn protruding the farthest into the cleft. This mode of binding
is unusual for the recognition of a large protein antigen, where
it is more common for the epitope to comprise a large flat surface
on the antigen (Sundberg and Mariuzza, 2002), as was observed
for the binding of cetuximab to EGFR (Li et al., 2005). All of the
key interactions made by the Fab are from the complementar-
ity-determining regions (CDRs), with the major specificity-deter-
mining contacts coming from CDRs H3 and L3. All of the CDRs
contribute to binding to domain III, also an unusual feature
compared to most antigen-antibody complexes (Sundberg and
Mariuzza, 2002).
The tip of the buried loop from sEGFR makes interactions with
both the heavy- and light-chain CDRs (Figure 3B); the side chain
of T459 interacts with that of H93 from the Fab light chain, while
the side chain of S460 contacts the CDR H2 side chain E50. Two
lysines, one on either end of the sEGFRd3 epitope loop, form salt
bridge interactions with aspartic acids on the Fab (K454 with
D100 from CDR H3 and K463 with CDR L2 D49). AdditionalCancer Cell 13, 365–373, April 2008 ª2008 Elsevier Inc. 367
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chains in CDRs H1, H2, and L1 that are within hydrogen-bonding
distance of the main chain of sEGFRd3 (Figure 3B and Figure S1
available online). Two important direct interactions are made
between the Fab and regions of domain III outside the loop
between amino acids 454–464. A histidine from CDR L3 (H93)
interacts with D434 on the adjacent loop of the sEGFRd3 b-helix,
while on the other side of the binding site Y103 from the apex of
CDR H3 extends to interact with N449. These two interactions
anchor the Fab over the central binding loop and expand the
epitope substantially beyond the single peptide loop.
A total of two salt bridges and 11 predicted hydrogen bonds
are involved in the interaction between Fab72000 and sEGFRd3,
in an interface that buries 758 A˚2 of solvent-accessible surface
on domain III (a total of 1516 A˚2 of surface is occluded from
solvent in the complex). The shape complementarity (sc) param-
eter for the interface of the Fab72000/sEGFRd3 complex is 0.62,
Table 1. Data Collection and Refinement Statistics
Fab72000 Fab72000/sEGFRd3
Data Collection Statisticsa
Space group P212121 C2
Unique cell
dimensions
a = 56.8 A˚,
b = 61.4 A˚,
c = 102.7 A˚
a = 141.1 A˚, b = 205.0 A˚,
c = 81.6 A˚, b = 117.5
X-ray source CHESS F1 SLS X06SA
Resolution limit 2.15 A˚ 3.2 A˚
Observed/unique 107,297/
20,191
120,206/33,886
Completeness (%) 99.9 (99.9) 99.7 (98.7)
Rsym
b 0.10 (0.42) 0.12 (0.35)
<I/s> 20.7 (3.6) 11.4 (3.4)
Refinement Statistics
Resolution limits 50–2.15 A˚ 50–3.2 A˚
No. of reflections/no.
test set
19,098/1029 32,028/1709
R factor (Rfree)
c 0.22 (0.26) 0.24 (0.29)
Model one Fab72000
molecule
two Fab72000/sEGFRd3
complexes
Protein aa 4–211 of
light chain; aa
1–224 of
heavy chain
aa 310–500 of mature
sEGFR with 13 saccharide
units; aa 1–211 of Fab light
chain; aa 1–135, 142–222 of
Fab heavy chaind
Water/ions 99 water
molecules; 2
sulfates
—
Total number of atoms 3209 8517
RMSD bond length (A˚) 0.012 0.015
RMSD bond angles () 1.35 1.6
a Numbers in parentheses refer to last resolution shell.
b Rsym = SjIh  <Ih>j/SIh, where <Ih> is the average intensity over symme-
try equivalent measurements.
c R factor = SjFo  Fcj/SFo, where summation is over data used in the
refinement; Rfree includes 5% of the data excluded from the refinement.
d Number of missing amino acids in the heavy and light chains differs in
the two complexes.368 Cancer Cell 13, 365–373, April 2008 ª2008 Elsevier Inc.slightly lower than is typically observed for antigen-antibody
interfaces (0.64 to 0.68) (Lawrence and Colman, 1993). The sc
values reported for cetuximab bound to EGFR (Li et al., 2005)
and for the pertuzumab and trastuzumab complexes with the
extracellular region ErbB2 (Cho et al., 2003; Franklin et al.,
2004) are all somewhat higher, in the range from 0.70 to 0.75,
perhaps reflecting the more convex shape of the matuzumab
epitope compared to those of these other antibody drugs.
Neither the conformation of sEGFRd3 nor that of Fab72000 is
significantly altered upon formation of the complex. There are
very minor differences in the side chain positions in both the
domain III epitope and in the CDRs of the Fab. Most notably,
Y103 in the VH domain is disordered in the unbound Fab and
becomes ordered on interacting with sEGFR. The elbow
angle changes by only 4 between the bound and unbound
Fab72000, which is in within the range expected due to dynamic
elbow flexibility (Stanfield et al., 2006).
Not only is the conformation of domain III unaltered by
Fab72000 binding, but also the location of the bound Fab72000
would not be expected to disrupt the tethered configuration of
sEGFR (Figure 1, left panel), the preferred solution conformation
of the receptor (Dawson et al., 2007), and the likely conformation
of the unliganded receptor at the cell surface. Fab72000 can
readily be docked onto its epitope on either of the two known
structures of tethered sEGFR (PDB IDs 1NQL and 1YY9) without
hindrance from any of the other domains of sEGFR.
The Matuzumab Epitope Is Distinct from the
Ligand-Binding Site on Domain III of sEGFR
To confirm that the crystallographically defined epitope for
matuzumab precisely represents what is seen in solution, we
generated site-specific alterations in sEGFR at key amino acids
in the domain III matuzumab epitope (Figures 3B and 4A). Each
alteration was introduced in the context of the full-length extra-
cellular domain and these altered sEGFR proteins expressed
and purified using appropriately baculovirus infected Sf9 cells.
Each purified, altered sEGFR was analyzed for binding to immo-
bilized Fab72000 and to immobilized EGF, exactly as described
(Li et al., 2005). Alteration to alanine of either of the two lysines on
the epitope loop (K454A or K463A) leads to an approximate
100-fold reduction in the affinity of sEGFR for Fab72000
(Figure 4B). Substitution of alanines at T459 and S460 (T459A/
T460A) also dramatically reduces the binding affinity. The
combination of either lysine to alanine substitution with T459A/
T460A abolishes all detectable interaction between sEGFR and
the immobilized Fab72000.
As shown in Figure 4A, the binding sites for matuzumab and for
EGF on domain III do not overlap. As would be predicted based
upon this observation, the sEGFR proteins with alterations in the
Fab72000 epitope bind to immobilized EGF with near wild-type
affinity (Figure 4B). This also confirms that the striking reduction
in binding affinity of these altered sEGFR proteins for Fab72000
is not due to a global disruption of the structure of domain III
of sEGFR. Finally, substitution of two amino acids that are known
to be critical for EGF binding (D355T/F357A) have negligible
effect on binding of sEGFR to Fab72000.
Not only is there no overlap of the epitope for matuzumab and
the ligand binding region on domain III, but a bound Fab72000
would impose no steric hindrance to the binding of EGF or of
Cancer Cell
Inhibition of EGFR by MatuzumabFigure 3. Structure of theComplex between
the Matuzumab Fab Fragment and Domain
III of sEGFR
(A) Cartoon of the Fab72000/sEGFRd3 complex.
Domain III is colored in gray with the epitope high-
lighted in red. The orientation of domain III is the
same as for the tethered sEGFR (left-hand view)
in Figure 1. Fab72000 is colored cyan for the light
chain and yellow for the heavy chain.
(B) A closeup view of the interactions between
Fab72000 and domain III of sEGFR. Domain III is
in gray with the secondary structure elements
highlighted in red. The VL and VH domains of
Fab72000 are in gray with cyan and yellow high-
lights, respectively. The CDRs of Fab72000 are
shown in cyan for L1, L2, and L3 of the VL domain, and in yellow for H1, H2, and H3 of the VH domain. The side chains of the amino acids participating in key
interactions are shown, colored as for the CDRs for the Fab and in pink for domain III. The amino acids are labeled on a cyan background for those from VL,
on a yellow background for VH, and in black for sEGFRd3. Distances consistent with hydrogen bonds are shown with dashed black lines.TGFa to domain III. With domain III from the Fab72000/sEGFRd3
complex overlaid on domain III from the sEGFR/EGF complex
(PDB ID 1IVO) the closest approach of the Fab and EGF is 9 A˚.
This is in stark contrast to the situation for cetuximab binding.
There is a high degree of overlap between the cetuximab and
EGF-binding sites on domain III (Figure 4C). The steric block of
this ligand-binding site is the primary mechanism of cetuxi-
mab-mediated inhibition of ligand-induced dimerization and
activation of EGFR (Li et al., 2005). Clearly the mechanism of
inhibition of EGFR activation by matuzumab must be different.
Figure 4. The Matuzumab Epitope Is Distinct from the Ligand-
Binding Site on Domain III
(A) A surface representation of domain III is shown in gray viewed in approxi-
mately the same orientation as in Figure 3. Amino acids on domain III that are
within 4 A˚ of Fab72000 (red) or of EGF (green) are indicated on this surface. The
amino acids that were altered (see [B]) are labeled in white.
(B) Surface Plasmon Resonance (SPR) analysis of the binding of altered
sEGFR proteins to immobilized Fab72000 or EGF. The equilibrium binding
KD values for each protein were determined exactly as described in the legend
to Figure 2A. The fold change in this KD value for each altered protein relative to
that for the binding of wild-type sEGFR to each immobilized ligand is plotted.
Error bars indicate the standard deviation on at least three independent sets of
measurements.
(C) The same surface representation of domain III as in (A) is shown with the
contacting amino acids for FabC225 in yellow, for EGF in green, and for the
region of overlap between FabC225 and EGF in blue.Implications for the Mechanism of Inhibition of EGFR
Activation by Matuzumab
If matuzumab does not directly block access of the ligand to the
domain III ligand-binding site, how does it prevent high-affinity
ligand binding, receptor dimerization, and activation? To under-
stand this, we consider the effect of the binding of Fab72000
upon the formation of the ligand-induced dimeric form of the
receptor. As shown in Figure 1, sEGFR undergoes a dramatic
domain rearrangement in going from the tethered inactive state
to the ligand-bound dimeric state (Burgess et al., 2003). Addi-
tional local structural changes in domain II are known to be key
for high-affinity ligand binding, receptor dimerization, and activa-
tion (Dawson et al., 2005; Ogiso et al., 2002). As shown in Fig-
ure 5, and discussed in detail below, when domain III from the
Fab72000/sEGFRd3 complex is overlaid on domain III from the
receptor in its extended, dimerization-competent conformation
(PDB ID 1MOX), there are direct clashes between the bound
Fab72000 and both domains I and II of the extended receptor.
With matuzumab bound to domain III of EGFR, the receptor
cannot undergo the large-scale domain rearrangement that is
required for dimerization. Further, the binding of Fab72000
blocks the critical local conformational changes in domain II.
With the receptor in the extended conformation, the N-termi-
nal region of the domain I clashes with the light chain of
Fab72000, preventing domain I from reaching the position that
is required for high-affinity ligand binding (indicated with an
arrow in Figure 5A). This is reminiscent in nature and extent to
clashes between the antigen-binding fragment of cetuximab
(FabC225) and domain I that were previously implicated as
part of the mechanism of inhibition of EGFR dimerization by
that antibody (Li et al., 2005). In that case, the different orienta-
tion of FabC225 on domain III positions the VH domain such as
to occlude the N-terminal portion of domain I from its required
position in the receptor dimer.
Clashes between domain II of the extended receptor and the
Fab were not seen in the cetuximab complex, and are significant.
With Fab72000 bound to domain III of EGFR, it would not be pos-
sible for the C-terminal portion of domain II to adopt the confor-
mation observed in the ligand-bound dimeric form of the
receptor. As shown in Figure 5B, if Fab72000 is docked onto
its epitope on domain III of an sEGFR molecule in the extended
conformation, there are clashes along the C-terminal half ofCancer Cell 13, 365–373, April 2008 ª2008 Elsevier Inc. 369
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C-terminal half of domain II forms the binding pocket for the
dimerization arm from the other molecule in the receptor dimer.
Additional interactions across the dimer interface from a C-ter-
minal loop on domain II (D279 and H280, marked with an asterisk
in Figure 5A) contribute substantially to the stability of the EGFR
dimer. The conformation of domain II in this region is stabilized
by interactions with domain III that have been demonstrated to
be critical for EGFR dimerization and activation (Dawson et al.,
2005; Ogiso et al., 2002). The binding of Fab72000 to domain
III would disrupt all of these interactions. Thus, Fab72000 binding
to domain III of EGFR blocks the global domain rearrangement of
EGFR and the local conformational changes in domain II. We
propose that blocking both of these key elements in formation
of the productive EGFR dimer is critical for the effective inhibition
of EGFR activation by matuzumab.
The steric restriction on EGFR conformation imposed by the
binding of matuzumab offers a structural framework to explain
the competition data presented in Figure 2. When matuzumab
(or just its antigen-binding domain, Fab72000) binds to the extra-
cellular region of EGFR, the receptor cannot adopt the confor-
mation required for both domains I and III to engage in ligand
binding. However, the ligand-binding site on domain III is
completely exposed. EGF can bind to this site with low affinity
(approximately 1 mM; Kohda et al., 1993; Lemmon et al., 1997;
Li et al., 2005). Under the conditions of the cell-based assay,
weak binding of EGF to only domain III of EGFR is not detected.
Figure 5. Implications for the Mechanism of Inhibition of EGFR by
Matuzumab
(A) Cartoon of the extended sEGFR with Fab72000, in surface representation,
docked onto its domain III epitope. The orientation of the receptor is the same
as for the right-hand protomer in the sEGFR dimer shown in Figure 1 (with
domains colored as for the left-hand protomer; EGF is omitted for clarity).
The Fab72000 is colored as in Figure 3. The N-terminal region of domain I
clashes with the VL domain (indicated with an arrow). Additional clashes occur
along the C-terminal half of domain II (see [B]). The C-terminal loop on domain
II (D278, H280) that makes critical contacts across the dimer interface is
marked with an asterisk.
(B) In this view, an approximate 50 rotation about the vertical axis relative to
(A), domain II is shown in sphere representation in dark green. A cartoon of do-
main II of the other molecule in the dimer is shown (light green) for reference.
Domain I has been omitted for clarity. The VL domain of the Fab clashes with
domain II in the critical C-terminal region that forms the binding pocket for the
dimerization arm and makes important contacts with domain III (from N274
and E293 in domain II, colored orange). These interactions are known to be
crucial for stabilizing the dimerization competent conformation of domain II.
The Fab72000 epitope loop on domain III is colored in red.370 Cancer Cell 13, 365–373, April 2008 ª2008 Elsevier Inc.By preventing the receptor from adopting the conformation
required for the bipartite binding of EGF between domains I
and III, matuzumab blocks all detectable binding of EGF to cell
surface EGFR in this assay. By contrast, the Biacore assay is
performed at a much higher concentration of soluble ligand (in
this case 600 nM sEGFR, which binds to immobilized EGF).
Under these conditions, the monovalent binding of domain III
alone to EGF can be detected. In the Biacore assay, the residual
binding to immobilized EGF observed for sEGFR in the presence
of excess Fab72000 is due, at least in part, to binding to EGF of
the exposed domain III in an Fab72000/sEGFR complex.
Implications for the Therapeutic Application
of Matuzumab
As discussed above, the mechanism of inhibition of matuzumab is
different from that previously described for cetuximab. Both anti-
bodies effectively block productive binding of EGF to cell surface
EGFR (Figure 2B) but do so by interacting with distinct epitopes
on domain III. Not only are the epitopes nonoverlapping, but the
structures suggest that both antibodies could simultaneously
bind to EGFR. As shown in Figure 6A, when FabC225 and
Fab72000 are simultaneously docked onto their respective epi-
topes on domain III the two Fab fragments occupy different posi-
tions and do not clash. This observation is consistent with cellular
competition assays. Excess cetuximab is unable to compete with
the binding of 125I-labeled matuzumab to the cell surface EGFR on
A431 cells (Figure 6B). Similarly matuzumab cannot compete for
125I-labeled cetuximab binding (Figure 6C). Further, it has been
reported that there are an increased number of cell surface anti-
body-binding sites for a mixture of matuzumab and cetuximab
compared to either antibody alone (Kreysch and Schmidt,
2004). This suggests that both matuzumab and cetuximab can
bind to a single receptor molecule at the cell surface.
Figure 6. The Matuzumab and Cetuximab Epitopes Do Not Overlap
(A) A surface representation of the domain III as in Figure 4 is shown. Cartoons
of Fab72000, FabC225 (PDB ID 1YY9), and EGF (PDB ID 1IVO) are shown
docked onto their respective binding sites on domain III. Fab72000 is colored
as in Figure 3A, FabC225 is shown with the heavy chain in orange and the light
chain in light green, and EGF is in purple.
(B and C) Competition of matuzumab (red triangles) or cetuximab (black trian-
gles) for binding of 125I-labeled matuzumab (B) or 125I-labeled cetuximab (C) to
A431 cells, performed and analyzed as described in Figure 2B.
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distinct epitopes on the extracellular domain of EGFR, and on
the related family member ErbB2, leads to enhanced receptor
internalization and degradation (Friedman et al., 2005), a factor
that contributes to the antitumor activity of many therapeutic
antibodies. Matuzumab and cetuximab can both bind simulta-
neously to EGFR, and this has the potential to lead to synergistic
antitumor effects. Combination of matuzumab and cetuximab
could thus be beneficial in cancer therapy.
Conclusion
EGFR dimerization requires a conformational reorganization of
the receptor extracellular region that is promoted by ligand bind-
ing to domains I and III (Figures 1 and 7). As shown schematically
in Figure 7, cetuximab acts as a competitive inhibitor, preventing
ligand-induced dimerization by directly blocking access of
ligand to the domain III ligand-binding site. By contrast, matuzu-
mab does not occlude the ligand-binding site on domain III.
Rather, matuzumab exploits a noncompetitive mechanism to
inhibit sEGFR dimerization and activation. Inhibition of ligand-in-
duced EGFR activation by matuzumab is entirely dependent on
sterically blocking the receptor from adopting the conformation
that is required for high-affinity ligand binding and dimerization.
These different mechanisms of inhibition suggest opportunities
to exploit multiple EGFR-targeting drugs to act synergistically
for optimal therapeutic gain.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
sEGFR and sEGFRd3 were expressed in baculovirus-infected Sf9 cells, purified
as described (Fergusonet al., 2000; Li et al., 2005) and used without modification
of their glycosylation state. Matuzumab (EMD72000) was provided by Merck
KGaA. The Fab fragment of matuzumab (Fab72000) was generated by papain
cleavage using the ImmunoPure Fab Preparation Kit (Pierce) and used without
additional purification. Fab72000/sEGFR complex was generated exactlyas de-
scribed (Li et al., 2005). To generate the complex with sEGFRd3, Fab was mixed
Figure 7. Matuzumab and Cetuximab Use Different Mechanisms to
Block Ligand-Induced EGFR Dimerization and Activation
In the center of the scheme, the ligand-induced sEGFR dimer is represented,
with domain I in red, domain II in green, domain III in gray with red border,
domain IV in gray with green border, and the ligand (E) in violet. The colors
for one protomer are lightened for contrast. On the left-hand side a scheme
is shown to illustrate the mechanism of inhibition of ligand-induced dimeriza-
tion by matuzumab. Fab72000 binds to domain III of sEGFR and sterically pre-
vents the receptor from adopting the conformation required for dimerization.
Importantly, Fab72000 blocks the local conformational changes in domain II
that are critical for both high-affinity ligand binding and dimerization. The inhi-
bition is noncompetitive; the ligand-binding site on domain III is not blocked.
This contrasts with the mechanism of inhibition previously reported for cetux-
imab (Li et al., 2005). FabC225 (right side) is a competitive inhibitor that blocks
the ligand-binding site on domain III. This is the primary mechanism of inhibi-
tion of ligand-mediated dimerization by cetuximab.with a 1.2-fold molar excess of sEGFRd3 and excess sEGFRd3 separated from
Fab72000/sEGFRd3 complex by SEC using a Bio-Silect SEC250 column
(Bio-Rad), equilibrated with 20 mM HEPES and 100 mM NaCl (pH 7.5).
Crystallization and Data Collection
Proteins were concentrated and buffer exchanged into 10 mM HEPES and
50 mM NaCl (pH 7.5) and crystallized using the hanging drop vapor diffusion
method. Large single crystals of Fab72000 were obtained by mixing equal
volumes (1 ml) of the Fab (13 mg/ml) with a solution containing 1.8 M ammo-
nium sulfate and 0.1 M MES (pH 6.5) and equilibrating over a reservoir of
this buffer at 20C. Crystals were flash frozen in reservoir solution that was
supplemented with 9% sucrose, 2% glucose, 8% glycerol, and 8% ethylene
glycol. X-ray diffraction data were collected at the Cornell High Energy
Synchrotron Source (CHESS) beamline F1, using an ADSC Quantum-210
CCD detector. Fab72000/sEGFRd3 was crystallized by mixing equal parts
(1 ml) of the SEC purified complex (14 mg/ml) with 1 M NaCl, 16% PEG
3350, and 50 mM MES (pH 6.0) and equilibrating over a reservoir of the
same buffer at 20C. Streak seeding was used to produce large single crystals
(0.53 0.13 0.15 mm) that were cryostabilized by serial transfer to solutions of
reservoir containing increasing concentrations of ethylene glycol. Following
transfer to the final cryostabilizer of reservoir plus 15% ethylene glycol, crys-
tals were flash frozen in liquid nitrogen. Data were collected at the Swiss Light
Source (SLS) beamline X06SA, using a Mar225 CCD detector. All data were
processed in HKL2000 (Otwinowski and Minor, 1997). Data collection statis-
tics are summarized in Table 1.
Structure Determination and Refinement
The structures of the Fab72000 and Fab72000/sEGFRd3 were solved by the
method of MR using the program PHASER (CCP4, 1994). To solve the Fab
structure, the coordinates for Fab2C4 (PDB ID 1L7I) (Vajdos et al., 2002)
were selected as the initial search model based on the sequence identity
between Fab2C4 and Fab72000. To solve the Fab72000/sEGFRd3 structure,
one of the two Fab fragments in the asymmetric unit was first located using the
refined Fab72000 coordinates as search model. With the position of this Fab
fragment fixed, a second search using the coordinates of domain III of sEGFR
(amino acids 310–500 from PDB ID 1YY9) located one of the sEGFRd3
molecules. Subsequently, the second Fab72000/sEGFRd3 complex in the
asymmetric unit was found. Coordinates were manually rebuilt in COOT
(Emsley and Cowtan, 2004) and refined using CNS (Bru¨nger et al., 1998) and
Refmac (CCP4, 1994). New maps were calculated following each iteration of
refinement, including solvent flattened maps with minimized model bias calcu-
lated using the program DM (CCP4, 1994). Refinement statistics are summa-
rized in Table 1.
SPR/Biacore-Binding Studies
Surface Plasmon Resonance (SPR)/Biacore studies were carried out using
a Biacore 3000 instrument at 25C in 10 mM Tris, 150 mM NaCl, 3 mM
EDTA, and 0.005% Tween-20 (pH 8.0). Fab72000 was immobilized on
a Biacore CM5 biosensor chip as follows: the CM-dextran matrix was acti-
vated with N-ethyl-N0-(dimethylaminopropyl)-carbodiimide hydrochloride
(EDC) and N-hydroxysuccinimide (NHS). Fab72000 (500 ng) was flowed over
this activated surface at a concentration of 5 mg/ml in 10 mM sodium acetate
(pH 5.0) at 5 ml per minute for 20 min. The remaining reactive sites were blocked
with 1 M ethanolamine-HCl (pH 8.5). Immobilized Fab fragment contributed
a signal of 1436 response units (RU). The surface was regenerated between
sEGFR injections with two 5 ml injections of 10 mM glycine and 1 M NaCl
(pH 2.5) to remove remaining bound sEGFR. EGF immobilization and
sEGFR-binding analysis were performed exactly as described (Ferguson
et al., 2000). Data were analyzed using Prism 4 (GraphPad Software, Inc.).
Cell-Based Binding Studies
125I-labeled EGF, matuzumab, and cetuximab were generated with specific ac-
tivities of 1750 Ci/mmol, 273 Ci/mmol, and 238 Ci/mmol, respectively. A431 epi-
dermoid carcinoma cells were plated in 96-well dishes and grown to 75%–90%
confluence. Cells were washed twice with ice-cold DMEM containing 1% BSA
(incubation medium) and incubated in this medium containing 3 nM radio-
labeled ligand plus the relevant cold competitor (200ml/well) for 6 hr at 4C. Cells
were washed three times with ice-cold incubation medium and were lysed withCancer Cell 13, 365–373, April 2008 ª2008 Elsevier Inc. 371
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Inhibition of EGFR by Matuzumab1 M NaOH (200 ml/well). The wells were washed with 200 ml of water, and liquid
scintillation counting was used to determine the counts of bound 125I-labeled
species. Data were analyzed using Prism 4 (GraphPad Software, Inc.).
Generation of sEGFR Epitope Mutations
Standard PCR-directed site-directed mutagenesis strategies were used to
produce the appropriate DNA in the pFastBac vector. The following mutations
were made: K454A, K463A, T459A/S460A, K454A/T459A/S460A, and T459A/
S460A/K463A. The generation of recombinant baculovirus, overexpression
in Sf9 cells, and protein purification were exactly as described before for
wild-type sEGFR (Ferguson et al., 2000).
ACCESSION NUMBERS
Coordinates of the Fab72000 and Fab72000/sEGFRd3 structures have been
deposited, with PDB ID codes 3C08 and 3C09, respectively.
SUPPLEMENTAL DATA
The Supplemental Data include one supplemental figure and can be found with
this article online at http://www.cancercell.org/cgi/content/full/13/4/365/DC1/.
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